Metastatic Clear Cell Renal Cell Carcinoma research hub

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

This study is looking at a new drug, casdatifan, combined with an existing one, cabozantinib, for advanced clear cell kidney cancer. It compares this combination to cabozantinib with a dummy drug (placebo) to see if it stops cancer growth for longer in patients who've already had immunotherapy.